"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.

In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA).

Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic drugs. Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds of those sales.

"Reflecting the stability and maturity of its economy and financial markets, Israel was recently upgraded to developed-market status," says fund expert Mark Salzinger.

In The Investor's ETF Report, he looks at iShares MSCI Israel Capped Investable Market ETF (NYSE: EIS), noting, "For a nation of just more than seven million people, Israel generates exceptional economic productivity."

"GDP per capita was recently $28,200, good for 49th in the world, very close to established developed markets like New Zealand and Italy.

The Cabot Benjamin Graham Value Letter focuses on stocks that meet the strict value criteria of the legendary investor. Here, J. Royden Ward looks to Teva Pharmaceutical (NASDAQ: TEVA), noting, "Teva is based in Israel and develops, makes and sells generic and proprietary-branded (store brand) drugs."

The advisor explains, "The company is one of the largest generic drug-producing companies in the world and, in addition, sells active ingredients to other pharmaceutical companies.

"Teva's aggressive acquisition and product development programs are driving strong sales growth. The company recently purchased U.S.-based Barr Pharmaceuticals for $7.5 billion. Barr will increase Teva's generic drug sales significantly in the U.S. and parts of Europe.

"As is the case with most countries in the Middle East, Israel rarely comes up in discussions of global 'safe havens', notes John Christy.

The editor of The Forbes International Investment Report explains, "But so far this year, Israel has been a pretty good place to hide from Wall Street's woes." Here he looks at one Israeli favorite, Cellcom Israel (NYSE: CEL).

"Putting stereotypes about risk aside, Israel offers a lot of interesting opportunities, even for fairly conservative investors. Cellcom Israel is a prime example. The company is Israel's largest mobile phone service provider, with sales of $1.6 billion in 2007.

"Since February 2007, the company has had a dual listing on both the New York and Tel Aviv stock exchanges. Discount Investment Corp. Ltd., one of Israel's largest business groups, owns just over 50% of the company.

"With 3.1 million subscribers, Cellcom has a 34% share of Israel's mobile telecom services market. Roughly three-quarters of Cellcom's subscribers are individuals, and the remaining 25% are corporate customers.

"Analysts estimate the worldwide market for generics will increase from $75 billion to $125 billion by 2012," says Michael Shulman.

In his ChangeWave Biotech Investor he states, "The key question for us is: Who is going to make the most money from these expirations? And the 800-pound gorilla in this market is our long-time holding, Teva Pharmaceuticals (NASDAQ: TEVA).

"Teva is the largest and best generics company in the world with $9.4 billion in sales in 2007 and the gap between it and its competitors is growing. Teva has 331 products on the market, 65% more than its closest competitor.

"More importantly, based on its business model of a mix of proprietary and generic drugs, the company's operating margins are 10 points higher than competitors and that gap is widening. In fact, in the United States, the number of prescriptions filled with Teva generics is 50% more than its closest competitor.

"Be clear on this point: When it comes to generics, size does matter. The more a company sells, the more profit and cash it has available to do research and acquire more generics to add to its product list -- and the beat goes on.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Elbit Medical Imaging Ltd. (NASDAQ: EMITF) -- my top speculative idea for 2008 -- is about to change its name to Elbit Imaging, following shareholder approval," notes Vivian Lewis in her Global Investing Pro. Vivian was the top performer in last year's Best Stocks report, with her selection of DryShips rising nearly 400%.

"EMITF is a subsidiary of Europe Israel (M.M.S.) Ltd., which operates in the construction, operation, management and sale of shopping and entertainment centers in Israel, Central and Eastern Europe, and India.

"The company also owns hotels, primarily in major European cities, and manages and sells hotels through its Elscint Ltd. subsidiary.

"The company is also involved in investments in the research and development, production, and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, through its subsidiary InSightec Ltd.